Science is additive. As a researcher makes a singular breakthrough or as a publication answers one research question, it opens the door to dozens more questions and ideas for other researchers to explore. Discovery upon discovery, one paper at a time, science strides forward. That’s why we are so thrilled to share that as of this month, there are over 100 customer publications leveraging Arima technology!
Arima is excited to announce the recipients of the 2021 Arima Genomics HiChIP Research Grant. The Huang Lab at Penn State will be using the Arima HiChIP kit to understand the role of long non-coding RNA in 3D genome organization in leukemia. The Xu Lab at Zhejiang University & University of Singapore will be studying interactions between enhancers and promoters in glioblastoma using HiChIP. Finally, Dr. Swapan Nath from the Oklahoma Medical Research Foundation plans to use HiChIP to study the mechanistic link between lupus GWAS loci and their target genes. Congratulations to our winners!
Arima Genomics, a biotechnology company at the forefront of innovation in spatial genomics, today announced the launch of its early access program for capture Hi-C.
Hi-C enables researchers to capture spatial interactions, which has yielded tremendous insight across various fields in genomics. While genome-wide Hi-C provides a global framework of genome organization, capture Hi-C shines when it comes to targeted analysis. By combining well established in-solution hybridization with Hi-C prepped libraries to enrich target regions, capture Hi-C allows researchers to conduct larger studies by reducing per-sample cost and to gain deeper biological insights through greater resolution over target regions.
The Vertebrate Genomes Project has announced their flagship study and other publications on genome assembly in a special issue of Nature. The study focuses on quality and seeks to standardize and optimize methods of genome assembly. The publications exhibit complete genomes of 16 species assembled over 5 years and represent the beginning of Phase 1 of the VGP project. Phase 1 of the study involves assembling genomes from one representative species from each of 260 orders. Phase 2 will focus on representative species from vertebrate families. These representatives will serve as reference genomes for assembling additional species’ genomes.
SAN DIEGO, Calif., April 16, 2021 -- Arima Genomics, Inc., a biotechnology company focused on accelerating the adoption of spatial genomics, and SCRUM Inc., a Japanese-based distributor, combine forces to distribute genomic tools to a broader customer base.
Epigenetics-based research tools and services company, Active Motif, Inc., announced today that it has launched an end-to-end Hi-C service in partnership with Arima Genomics, Inc. to investigate the three-dimensional folding patterns of the genome, providing researchers with greater access to this powerful technology and advancing their research.
The launch of this Hi-C service extends Active Motif’s 15 years of experience and expertise offering Epigenetic Services, such as ChIP-Seq and ATAC-Seq services, and now allows researchers to gain a deeper understanding of the biological mechanisms at play in their clinical samples or experimental systems. Active Motif continues to offer the most comprehensive offering of epigenetic services in the industry, and this new Hi-C service gives researchers even more ways to analyze their samples.
Hi-C is the predominant method used by the research community and multiple large consortia such as ENCODE and 4D Nucleome to investigate how genome folding and mis-folding impacts gene accessibility, regulation, and expression, and its impact on disease states. Active Motif has entered into an agreement with Arima Genomics, a leading company accelerating the spatial understanding of the genome, to launch their end-to-end Hi-C service as an Active Motif Epigenetic Service to serve academic, pharma, and clinical researchers.
“This is an important strategic collaboration for both organizations,” said Fritz Eibel, Chief Commercial Officer at Active Motif. “There are several commercially available Hi-C kits and our validation has shown that the Arima-HiC+ kits provide superior data resolution, ease of use, and reproducibility. These requirements are essential to study genetics and epigenetics in both the biopharma and translational medicine settings where precious patient samples are investigated.”
“We are excited that Active Motif, a thought leader and major player in the epigenetics market, compared, validated, and selected Arima versus other options,” said Siddarth Selvaraj, CEO of Arima Genomics. “We believe that the spatial genome information is an indispensable complement to the genome sequence when used for medical research, diagnosis, and therapy development. In addition to our recent selection by the Wellcome Sanger Insitute, this collaboration with Active Motif is a significant step in the company’s goal of delivering market-leading science and to democratize the access of this essential technology.”
Active Motif is the industry leader in developing and delivering innovative tools and custom services to enable epigenetics and gene regulation research for the life science, clinical, pharmaceutical, and drug discovery communities. The company has a world-leading portfolio of assays, reagents, and genome-wide analysis services in the field of epigenetics and gene regulation. Active Motif operates globally through its corporate headquarters in Carlsbad, California, with regional headquarters in Belgium, Japan, and China, and has a worldwide network of sales and support offices. Active Motif applies a multi-disciplinary approach to create new and modify existing technologies to meet the current and future needs of life science researchers.
Arima Genomics, based in San Diego, California, is a biotechnology company that aims to accelerate the understanding of spatial genomics toward discovery, diagnosis and therapy.
SAN DIEGO--(BUSINESS WIRE)--Arima Genomics, Inc., a biotechnology company accelerating the adoption of the genome structure information, announced today that its new high-coverage HiC technology has been evaluated and implemented at the Wellcome Sanger Institute for projects, including the Darwin Tree of Life project, in an effort to explore the true genetic diversity between species and between individuals within a species.
SAN DIEGO--(BUSINESS WIRE)--Arima Genomics, Inc., a biotechnology company focused on accelerating the adoption of genome structure information toward medical research, diagnosis and therapy, announced today the full commercial launch of the HiChIP application built on its existing Arima-HiC platform. With this launch, researchers can now obtain long-range chromatin interactions specifically enriched at genomic locations occupied by proteins of interest from a single experiment, enabling speed to discovery and publication with reduced costs.
SAN DIEGO--(BUSINESS WIRE)--Arima Genomics, Inc., a company focused on research tools to accelerate the understanding of genome sequence and structure toward their role in human health and disease, announces that it has completed its Series A round of financing. Agilent Technologies, Inc. (NYSE: A) and Cowin Venture led this round, joined by Vectr Ventures and Berkeley Catalyst Fund.
The Genome 10K’s Vertebrate Genomes Project (VGP) and the Earth BioGenome Project (EBP) are moving ahead in their quests to sequence the genomes of all living vertebrate species and all eukaryotic species, respectively.
Google Maps in 3D accelerates our understanding of direction and travel, likewise, ability to view genomes in 3D accelerates our understanding of the role genetics plays in human health and disease.
Two ongoing efforts to produce new human genome assemblies are combining ultra-long nanopore reads with other types of sequencing and mapping data to generate gapless or near-gapless assemblies that can serve as reference genomes for future studies.
Gene regulation is offering a new class of targets that operate on a higher level than DNA sequences and epigenetic markers: 3-D genomic structures. While strategies to drug the 3-D genome are still in their infancy, the growing accessibility of mapping technologies is paving the way for translation in cancer and developmental disorders.
Arima Genomics introduces enhanced Arima-HiC product offering to drive greater insights for chromatin conformation and genome assembly studies
The Genome 10K consortium (G10K) announces the official launch of the Vertebrate Genome Project (VGP) and its first release of 15 new, high-quality reference genomes for 14 species representing all five vertebrate classes – mammals, birds, reptiles, amphibians, and fishes. As a selected partner for the current Phase 1 of VGP, Arima Genomics delivered high quality Hi-C proximity-ligation (referred to as Arima-HiC) data necessary to achieve whole chromosome-spanning assemblies.
